Heart failure drug flaw revealed in new study
NCT ID NCT07281014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why standard heart failure medications may not fully block a hormone called aldosterone. Researchers will give 20 adults with stable heart failure either a placebo or the drug spironolactone, then measure how the body handles salt and water. The goal is to understand the biology behind treatment gaps, not to test a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?